How can we use crenolanib to treat AML?

Share :
Published: 5 Dec 2016
Views: 3422
Rating:
Save
Dr Eunice Wang - Roswell Park Cancer Institute, New York, USA

Dr Wang meets with ecancer at ASH 2016 to discuss crenolanib, a type I FLT3 TKI inhibitor, that can be safely combined with cytarabine and anthracycline induction chemotherapy.

This results in high response rates in patients with newly diagnosed FLT3 mutant acute myeloid leukaemia (AML).

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.